Alnylam Pharmaceuticals | ALNY - Umsatzkosten

Aktienkurs
311.10
Täglich Wechseln
-3.70 -1.18%
Monatlich
-7.46%
Jährlich
22.70%
Q1 Prognose
303.95




Umsatzkosten Veränderung Datum
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
Agios Pharmaceuticals USD 1.88M 199K 2025-12
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
Amgen USD 1.79B 128M 2025-12
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Incyte USD 121.18M 22.18M 2025-12
Ionis Pharmaceuticals USD 8M 5.66M 2025-12
Moderna USD 452M 245M 2025-12
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Novartis USD 3.54B 7M 2025-12
PTC Therapeutics USD 16.3M 7.02M 2025-12
Regeneron Pharmaceuticals USD 584.6M 63M 2025-12
Sangamo BioSciences 2.42M 1.11M 2024-06
Sanofi EUR 3.76B 344M 2025-12
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Takeda JPY 401.15B 184.07B 2025-12
Ultragenyx Pharmaceutical USD 29M 1.01M 2025-12
Vertex Pharmaceuticals USD 466M 51.2M 2025-12
Xencor USD 61.66M 50.95M 2025-06